Novel Relationship between Mitofusin 2-Mediated Mitochondrial Hyperfusion, Metabolic Remodeling, and Glycolysis in Pulmonary Arterial Endothelial Cells

• Published in: International journal of molecular sciences Vol. 24; no. 24; p. 17533
• Main Authors: Yegambaram, Manivannan, Sun, Xutong, Flores, Alejandro Garcia, Lu, Qing, Soto, Jamie, Richards, Jaime, Aggarwal, Saurabh, Wang, Ting, Gu, Haiwei, Fineman, Jeffrey R, Black, Stephen M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-12-2023
• Subjects: Adenosine Triphosphate - metabolism; Animals; Apoptosis; Bioenergetics; Cell growth; Dehydrogenases; Discriminant analysis; Endothelial Cells - metabolism; Genotype & phenotype; Glucose; Glycolysis; GTP Phosphohydrolases - metabolism; Hydrolases - metabolism; Hypertension, Pulmonary - metabolism; Metabolism; Metabolites; metabolomics; Mitochondria; Mitochondria - metabolism; Mitochondrial Dynamics; mitochondrial function; Mitochondrial Proteins - metabolism; mitofusin; Oxidation; Phosphorylation; Proteins; pulmonary hypertension; Reactive Oxygen Species - metabolism; Sheep; mitochondrial function; metabolomics; mitofusin; pulmonary hypertension; glycolysis
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242417533

The disruption of mitochondrial dynamics has been identified in cardiovascular diseases, including pulmonary hypertension (PH), ischemia-reperfusion injury, heart failure, and cardiomyopathy. Mitofusin 2 (Mfn2) is abundantly expressed in heart and pulmonary vasculature cells at the outer mitochondrial membrane to modulate fusion. Previously, we have reported reduced levels of Mfn2 and fragmented mitochondria in pulmonary arterial endothelial cells (PAECs) isolated from a sheep model of PH induced by pulmonary over-circulation and restoring Mfn2 normalized mitochondrial function. In this study, we assessed the effect of increased expression of Mfn2 on mitochondrial metabolism, bioenergetics, reactive oxygen species production, and mitochondrial membrane potential in control PAECs. Using an adenoviral expression system to overexpress Mfn2 in PAECs and utilizing
C labeled substrates, we assessed the levels of TCA cycle metabolites. We identified increased pyruvate and lactate production in cells, revealing a glycolytic phenotype (Warburg phenotype). Mfn2 overexpression decreased the mitochondrial ATP production rate, increased the rate of glycolytic ATP production, and disrupted mitochondrial bioenergetics. The increase in glycolysis was linked to increased hypoxia-inducible factor 1α (HIF-1α) protein levels, elevated mitochondrial reactive oxygen species (mt-ROS), and decreased mitochondrial membrane potential. Our data suggest that disrupting the mitochondrial fusion/fission balance to favor hyperfusion leads to a metabolic shift that promotes aerobic glycolysis. Thus, therapies designed to increase mitochondrial fusion should be approached with caution.